A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy

BACKGROUND: In this single-arm phase II study (NCT03557099), we evaluated the efficacy and safety of hetrombopag, a small molecule thrombopoietin (TPO) receptor agonist, in patients with severe aplastic anemia (SAA) who were refractory to standard first-line immunosuppressive therapy (IST). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Guangxin, He, Guangsheng, Chang, Hong, Gao, Sujun, Liu, Xinjian, Chen, Tong, Li, Pei, Han, Bing, Miao, Miao, Ge, Zheng, Ge, Xiaoyan, Li, Fei, Li, Yingmei, Wang, Shunqing, Wang, Yi, Shen, Yaqi, Zhang, Tao, Zou, Jianjun, Zhang, Fengkui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972928/
https://www.ncbi.nlm.nih.gov/pubmed/35371427
http://dx.doi.org/10.1177/20406207221085197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972928/
https://www.ncbi.nlm.nih.gov/pubmed/35371427
http://dx.doi.org/10.1177/20406207221085197

Ejemplares similares